Catalyst Pharmaceuticals Inc (CPRX)
21.12
-0.03
(-0.14%)
USD |
NASDAQ |
Nov 21, 16:00
21.12
0.00 (0.00%)
After-Hours: 20:00
Catalyst Pharmaceuticals Net Income (Quarterly): 43.88M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 43.88M |
| June 30, 2024 | 40.79M |
| March 31, 2024 | 23.28M |
| December 31, 2023 | 34.84M |
| September 30, 2023 | -30.76M |
| June 30, 2023 | 37.76M |
| March 31, 2023 | 29.57M |
| December 31, 2022 | 25.47M |
| September 30, 2022 | 22.75M |
| June 30, 2022 | 21.62M |
| March 31, 2022 | 13.24M |
| December 31, 2021 | 9.309M |
| September 30, 2021 | 10.33M |
| June 30, 2021 | 12.18M |
| March 31, 2021 | 7.663M |
| December 31, 2020 | 11.44M |
| September 30, 2020 | 43.34M |
| June 30, 2020 | 9.78M |
| March 31, 2020 | 10.43M |
| December 31, 2019 | 7.929M |
| September 30, 2019 | 13.63M |
| June 30, 2019 | 10.96M |
| March 31, 2019 | -0.6445M |
| December 31, 2018 | -14.50M |
| September 30, 2018 | -7.839M |
| Date | Value |
|---|---|
| June 30, 2018 | -5.965M |
| March 31, 2018 | -5.700M |
| December 31, 2017 | -5.388M |
| September 30, 2017 | -4.178M |
| June 30, 2017 | -3.880M |
| March 31, 2017 | -4.967M |
| December 31, 2016 | -4.163M |
| September 30, 2016 | -3.954M |
| June 30, 2016 | -4.569M |
| March 31, 2016 | -5.386M |
| December 31, 2015 | -5.815M |
| September 30, 2015 | -4.449M |
| June 30, 2015 | -4.558M |
| March 31, 2015 | -5.410M |
| December 31, 2014 | -3.49M |
| September 30, 2014 | -5.010M |
| June 30, 2014 | -3.198M |
| March 31, 2014 | -3.811M |
| December 31, 2013 | -1.355M |
| September 30, 2013 | -5.912M |
| June 30, 2013 | -3.144M |
| March 31, 2013 | -1.744M |
| December 31, 2012 | -0.0766M |
| September 30, 2012 | -2.622M |
| June 30, 2012 | -0.2891M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-30.76M
Minimum
Sep 2023
43.88M
Maximum
Sep 2024
19.24M
Average
17.43M
Median
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 47.21M |
| Vertex Pharmaceuticals Inc | 1.045B |
| Sarepta Therapeutics Inc | 33.61M |
| ADMA Biologics Inc | 35.91M |
| BioVie Inc | -4.152M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 128.70M |
| Total Expenses (Quarterly) | 77.79M |
| EPS Diluted (Quarterly) | 0.35 |
| Enterprise Value | 2.077B |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | 34.10% |
| Earnings Yield | 5.59% |
| Operating Earnings Yield | 6.76% |
| Normalized Earnings Yield | 5.599 |